From June 1 to 8, 2023, Zhang Yong, Director of Department of Surgical Oncology of the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU), was invited to attend American Society of Clinical Oncology (ASCO) Annual Meeting (ASCO 2023) in McCormick Convention Center in Chicago. The theme of ASCO 2023 is "Partnering with Patients: The Cornerstone of Cancer Care and Research". The meeting not only shared and discussed current international cutting-edge clinical oncology research achievements and tumor treatment technologies, but also discussed how the interaction between clinicians and patients has changed over the years. During ASCO 2023, researchers announced a series of novel progresses in immunotherapy, including new immune checkpoint inhibitors and combined immunotherapy, etc. In addition to immunotherapy, gene editing technology has also become a hot topic. The emergence of gene editing technology provides a new possibility for cancer care. The field of oncology is developing at an unprecedented speed. With the progress of science and technology and the deepening of research, more innovative treatment methods are expected to emerge in the future, bringing better hope for the survival of cancer patients.